Clik here to view.
CANbridge Life Sciences Appoints Chief Medical Officer
BEIJING CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that it strengthened the executive management team with the...
View ArticleClik here to view.
Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion...
DEERFIELD, Ill. Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced the CE marking of the Evo IQ Infusion System. In addition to the...
View ArticleClik here to view.
Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I...
View ArticleClik here to view.
三叶草生物制药在中国开展的依那西普生物类似药SCB-808 I期临床试验入组首例受试者
成都 三叶草生物制药，一家致力于创新及变革性生物制药研发的生物制药公司，今天宣布在中国进行的SCB-808 I期临床试验入组首例受试者。该药物是一种预充填小容量注射液Enbrel®（依那西普）的生物类似药，用于治疗类风湿性关节炎和其他自身免疫性疾病。...
View ArticleClik here to view.
Genome Editing Biotech EdiGene Names Dong Wei, Ph.D., MBA as its Chief...
BEIJING & CAMBRIDGE, Mass. EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Mitsui and Kirin Make a Strategic Investment in Thorne
NEW YORK Thorne today announced it has entered into an agreement for a joint strategic investment with Mitsui & Co., Ltd. (Mitsui) and Kirin Holdings Company, Limited (Kirin). The strategic...
View ArticleClik here to view.
Taro to Announce First Quarter Results on August 9, 2018
HAWTHORNE, N.Y. Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2018, after the close of market on...
View ArticleClik here to view.
China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir,...
FOSTER CITY, Calif. Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine...
View ArticleClik here to view.
KIST: Overcoming the Current Limitations of Cancer Immunotherapy Through...
SEOUL, South Korea Cancer immunotherapy harnessing the immune system to treat cancer is drawing a lot of attention of many medical staff and researchers because of unprecedented responses in the...
View ArticleClik here to view.
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License...
SAN DIEGO & MELBOURNE, Australia ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American...
View ArticleClik here to view.
和铂医药与Glenmark Pharmaceuticals签署同类首创双特异性抗体药物战略合作与独家授权协议
中国上海，美国波士顿，印度孟买和瑞士La Chaux de Fonds (美国商业资讯)–全球化的生物制药公司和铂医药与Glenmark Pharmaceuticals S.A. 宣布签署一项独家授权协议，在大中华区开发、生产以及商业化GBR 1302。这是一种由Glenmark开发的用于治疗HER2阳性癌症的靶向HER2和CD3的双特异性抗体创新药物。...
View ArticleClik here to view.
Harbour BioMed and Glenmark Pharmaceuticals Sign Agreement for Greater China...
BOSTON & SHANGHAI & MUMBAI, India & LA CHAUX DE FONDS, Switzerland Harbour BioMed and Glenmark Pharmaceuticals S.A., announced today that they have entered into an exclusive license...
View ArticleClik here to view.
Synergy Pharmaceuticals Announces License Agreement with Luoxin...
NEW YORK Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) announced today that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing...
View ArticleClik here to view.
Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and...
View ArticleClik here to view.
Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class...
REDWOOD CITY, Calif. & OSAKA, Japan Ambys Medicines, a biotechnology company focused on the discovery and development of transformative therapies for people with serious liver disease, and...
View ArticleClik here to view.
Genome Editing Biotech Company EdiGene Raises $15 Million in Series pre-B...
BEIJING & CAMBRIDGE, Mass. EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
2018年上期における米国FDA新薬承認申請の95%をCertara社のソフトウェアやサービスがサポート
ニュージャージー州プリンストン モデルを活かした医薬品開発、レギュラトリー・サイエンス、市場アクセスおよびリアルワールド・エビデンス・サービスの分野で世界をリードするCertara®社は、2018年上期の米国食品医薬品局 (FDA)...
View ArticleClik here to view.
Certara Software or Services Supported 95% of the US FDA Novel Drug Approvals...
PRINCETON, N.J. Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today reported that 95% of novel new drug...
View ArticleClik here to view.
AVITA Medical Announces Expanded Compassionate Use of RECELL® Device in...
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, OTCQX: AVMXY) today announced that the U.S. Food and Drug Administration (FDA) has approved a significant increase in the number...
View ArticleClik here to view.
Modulus Raises 800M Japanese Yen for Its Series A Funding Round
TOKYO Modulus Discovery, Inc., an early stage drug discovery company announced today that it has successfully raised a total of 800M Japanese Yen (approximately US $7.2M) for its series A round, led...
View Article